Guggenheim Reaffirms Buy Rating for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Guggenheim in a research report issued on Monday,Benzinga reports. They currently have a $33.00 price objective on the biopharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 29.25% from the company’s previous close. A number of other […]